Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Total Non-Current Liabilities (2024 - 2025)

Rein Therapeutics (RNTX) has disclosed Total Non-Current Liabilities for 2 consecutive years, with $7.2 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 3.74% to $7.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.2 million through Dec 2025, down 3.74% year-over-year, with the annual reading at $7.2 million for FY2025, 3.74% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $7.2 million at Rein Therapeutics, down from $7.5 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $9.5 million in Q2 2025, with the low at $7.2 million in Q4 2025.